Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr)

Christoph T. Behrendt, Andrea Kunfermann, Victoria Illarionova, An Matheeussen, Miriam K. Pein, Tobias Gräwert, Johannes Kaiser, Adelbert Bacher, Wolfgang Eisenreich, Boris Illarionov, Markus Fischer, Louis Maes, Michael Groll, Thomas Kurz

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Abstract

Reverse hydroxamate-based inhibitors of IspC, a key enzyme of the non-mevalonate pathway of isoprenoid biosynthesis and a validated antimalarial target, were synthesized and biologically evaluated. The binding mode of one derivative in complex with EcIspC and a divalent metal ion was clarified by X-ray analysis. Pilot experiments have demonstrated in vivo potential.

Original languageEnglish
Pages (from-to)6796-6802
Number of pages7
JournalJournal of Medicinal Chemistry
Volume54
Issue number19
DOIs
StatePublished - 13 Oct 2011

Fingerprint

Dive into the research topics of 'Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr)'. Together they form a unique fingerprint.

Cite this